公开(公告)号：NO20026239A

公开(公告)日：2003-02-27

申请号：NO20026239

申请日：2002-12-27

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD WOODWARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68

CPC classification number: C07K16/245 ,  A61K47/6845 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/10 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  G01N33/6869

公开(公告)号：NO20023788D0

公开(公告)日：2002-08-09

申请号：NO20023788

申请日：2002-08-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD WOODWARD ,  ROGUSKA MICHAEL ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN G ,  DUNCAN ALEXANDER R ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN A ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  A61K45/00 ,  C12N15/02 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：NO20026239D0

公开(公告)日：2002-12-27

申请号：NO20026239

申请日：2002-12-27

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD WOODWARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  C12N

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：NO20026239L

公开(公告)日：2003-02-27

申请号：NO20026239

申请日：2002-12-27

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD WOODWARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.